Advanced search×

A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis.

David B DB Granet, Mark M Dorfman, David D Stroman, and Paul P Cockrum

J Pediatr Ophthalmol Strabismus 45(6):340-9 (2008) PMID 19043945

To compare the speed of clinical efficacy for two currently available topical antibiotics: polymyxin B sulfate/trimethoprim (polymyxin/trimethoprim) and 0.5% moxifloxacin ophthalmic solution.

Version: za2963e q8za8 q8zb3 q8zce q8zd4 q8zef q8zf8 q8zg9

Similar articles you may find interesting…

  1. What is a clinical pearl and what is its role in medical education?
    Martin I MI Lorin, Debra L DL Palazzi, ... Mark A MA Ward

    Audio, Transactions of the IRE Professi... 30(9-10):870-4 (2008) PMID 18821165

    While there are no universally accepted criteria for preparing or evaluating a clinical pearl, we propose some rational guidelines for both....
  2. Moxifloxacin versus polymyxin B/trimethoprim sulfate in pediatric bacterial conjunctivitis.
    Rudolph S RS Wagner

    J Pediatr Ophthalmol Strabismus 45(6):330 (2008) PMID 19043943

  3. Comparison of azithromycin and moxifloxacin against bacterial isolates causing conjunctivitis.
    Christina C Ohnsman, David D Ritterband, ... Al A Kabat

    Curr Med Res Opin 23(9):2241-9 (2007) PMID 17688706

    Resistance to azithromycin is more common than resistance to moxifloxacin in clinical isolates causing bacterial conjunctivitis....